FDA interchangeable biosimilar designation — enabling pharmacist substitution of biosimilar for reference biologic without prescriber notification analogous to generic drug substitution — represents a regulatory milestone that is transforming US biosimilar adoption beyond prescriber-level prescribing decisions, with the Biosimilars Market reflecting interchangeability's commercial...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)